Chai Discovery Eli Lilly AI drug discovery: A $1.3 billion leap for biotech
Chai Discovery lands a $1.3B valuation and partners with Eli Lilly for AI-powered drug discovery. Explore the OpenAI-backed startup's journey and its Chai-2 algorithm.
In just over 12 months, Chai Discovery has gone from a stealthy startup to a $1.3 billion heavyweight. By securing $130 million in Series B funding this December, the company is positioning itself as the "CAD suite" for molecular design, aiming to replace expensive trial-and-error with precision AI.
The Chai Discovery Eli Lilly AI drug discovery deal
Last Friday, the startup announced a milestone partnership with pharmaceutical giant Eli Lilly. Lilly will utilize Chai’s flagship algorithm, Chai-2, to design therapeutic antibodies—the specialized proteins used to combat complex diseases. This collaboration isn't just a pilot; it's a strategic move to push the frontier of how generative AI can build better molecules from scratch.
Born from the OpenAI inner circle
Chai’s rapid ascent is no accident. Co-founders Josh Meier and Jack Dent have deep ties to OpenAI and its CEO, Sam Altman. Meier, a former OpenAI researcher, was encouraged by Altman years ago to start a proteomics firm. OpenAI eventually became an early investor, even providing office space in San Francisco during the company's infancy. Meier’s previous work at Facebook on the ESM1 protein-language model serves as the technological precursor to Chai’s current innovations.
| Entity | Partnership Role | Value/Focus |
|---|---|---|
| Eli Lilly | Strategic Partner | Antibody Design |
| Nvidia | Co-innovation Lab | $1 Billion investment |
| OpenAI | Seed Investor | Early support & space |
This content is AI-generated based on source articles. While we strive for accuracy, errors may occur. We recommend verifying with the original source.
Related Articles
Max Hodak's Science Corp raises $230M for rice-grain sized chip that restores vision to blind patients. Could beat Neuralink as first BCI company to commercialize
Trump appointee overruled FDA scientists to reject Moderna's mRNA flu vaccine, then reversed course within a week after public backlash. Political interference in vaccine approval raises concerns.
EV startup Ever raises $31M to reimagine car retail with AI-native approach, challenging traditional dealership model with integrated digital-physical experience.
Newly released DOJ documents reveal Jeffrey Epstein's attempts to invest in Lucid Motors, Faraday Future, and Canoo through mysterious intermediary David Stern.
Max Hodak's Science Corp raises $230M for rice-grain sized chip that restores vision to blind patients. Could beat Neuralink as first BCI company to commercialize
Trump appointee overruled FDA scientists to reject Moderna's mRNA flu vaccine, then reversed course within a week after public backlash. Political interference in vaccine approval raises concerns.
EV startup Ever raises $31M to reimagine car retail with AI-native approach, challenging traditional dealership model with integrated digital-physical experience.
Newly released DOJ documents reveal Jeffrey Epstein's attempts to invest in Lucid Motors, Faraday Future, and Canoo through mysterious intermediary David Stern.
Thoughts
Share your thoughts on this article
Sign in to join the conversation